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S U M M A R Y
Objectives: Information is lacking on the methicillin-resistant Staphylococcus aureus (MRSA) clonal
lineages circulating in Bolivia. We investigated the prevalence and molecular epidemiology of S. aureus
colonization in hospitalized patients from the Bolivian Chaco, and compared their features with those of
the few clinical isolates available from that setting.
Methods: S. aureus nasal/inguinal colonization was investigated in 280 inpatients from eight hospitals in
two point prevalence surveys (2012, n = 90; 2013, n = 190). Molecular characterization included
genotyping (spa typing, multilocus sequence typing, and pulsed-ﬁeld gel electrophoresis), detection of
virulence genes, and SCCmec typing.
Results: Forty-one inpatients (14.6%) were S. aureus nasal/inguinal carriers, of whom ﬁve were colonized
by MRSA (1.8%). MRSA isolates mostly belonged to spa-type t701, harboured SCCmec IVc, and were
negative for Panton–Valentine leukocidin (PVL) genes. However, a USA300-related isolate was also
detected, which showed the characteristics of the USA300 Latin American variant (USA300-LV; i.e., ST8,
spa-type t008, SCCmec IVc, presence of PVL genes, absence of arcA). Notably, all the available MRSA
clinical isolates (n = 5, collected during 2011–2013) were also identiﬁed as USA300-LV.
Conclusions: Overall, MRSA colonization in inpatients from the Bolivian Chaco was low. However,
USA300-LV-related isolates were detected in colonization and infections, emphasizing the importance of
implementing control measures to limit their further dissemination in this resource-limited area.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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The worldwide emergence and dissemination of methicillin-
resistant Staphylococcus aureus (MRSA) has signiﬁcantly reduced
the therapeutic options for staphylococcal infections and
worsened their clinical outcome.1 MRSA isolates are resistant
to virtually all beta-lactams (except the newer anti-MRSA* Corresponding authors. Tel.: +39 055 7949482; fax: +39 055 7949431.
Tel.: +39 055 7949239; fax: +39 055 7949289.
E-mail addresses: alessandro.bartoloni@uniﬁ.it (A. Bartoloni),
gianni.rossolini@gmail.com, gianmaria.rossolini@uniﬁ.it (G.M. Rossolini).
http://dx.doi.org/10.1016/j.ijid.2014.12.006
1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).compounds) due to the expression of low-afﬁnity penicillin-
binding proteins (PBPs), encoded by the mecA or mecC genes,
which can overtake the functions of the other PBPs.1,2 The mec
genes are carried by particular mobile genetic elements prevalent
in staphylococci, named staphylococcal cassette chromosome
(SCC) elements, with 11 types of SCCmec having been character-
ized so far.2
MRSA has been disseminating across virtually all geographical
areas for decades, arising as a major pathogen in both the hospital
and community setting, with a limited number of highly successful
clonal lineages being responsible for most MRSA epidemics
worldwide.3 The surveillance of MRSA clones (both from infections
and colonization) is crucial for the implementation of effectiveciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Figure 1. Location of the centres involved in the study. The study involved eight
hospitals: Monteagudo (Hospital San Antonio de Los Sauces, Hospital
Dermatologico); Charagua (Hospital Mamerto Eguez Soruco); Camiri (Hospital
Municipal de Camiri); Villa Montes (Hospital de Villa Montes); Caraparı´ (Hospital
de Caraparı´); Entre Rios (Hospital de Entre Rios); Yacuiba (Hospital de Yacuiba).
Hospitals with patients colonized by Staphylococcus aureus are marked with an
asterisk and the number of patients carrying MRSA is reported in brackets.
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understand the diverse evolutionary trajectories of MRSA lineages
on a worldwide scale.3
Latin America is not an exception to the global increasing
prevalence of MRSA infections, and a number of reports have
described the epidemiological and molecular features of MRSA
clonal lineages circulating in this geographic area over the past two
decades.4,5 Two major MRSA clones, namely the Brazilian clone
MRSA-ST239-IIIA (belonging to sequence type (ST) 239 and
harbouring SCCmec IIIA) and the Cordobes/Chilean clone MRSA-
ST5-I, have accounted for the early emergence and dissemination
of MRSA in the hospital setting in several Latin American
countries.4–6 Regarding the community setting, three major MRSA
lineages producing the Panton–Valentine leukocidin (PVL) have
been described in Latin America: MRSA-ST30-IV and MRSA-ST5-IV,
mainly disseminated in southern countries,4,7,8 and MRSA-ST8-IVc,
predominant in northern countries.4,9–12 The latter is genetically
related to the USA300 MRSA pandemic clone, but harbours a
different SCCmec IV subtype (IVc instead of IVa) and typically lacks
the arginine catabolic mobile element (ACME).9 MRSA-ST8-IVc
(sometimes referred to as USA300-LV, for USA300 Latin American
variant) has recently been acknowledged as the major clone
responsible for both community and hospital MRSA infections in
Colombia.11–13
Bolivia is one of the poorest countries of Latin America, and in
many rural areas the healthcare system relies on small hospitals
that have no access to clinical microbiology diagnosis and limited
resources for the implementation of infection control measures. An
MRSA prevalence of 49% has been reported recently,14 but data on
MRSA clonal lineages circulating in this country are lacking, and
very few data are available on the dissemination of MRSA in rural
areas.15,16
In a previous surveillance study on MRSA nasal carriage, we
documented a low MRSA prevalence (range 0–1.5%) among
healthy individuals from the Bolivian Chaco, a resource-limited
region of Bolivia.16 In this work we investigated, for the ﬁrst time,
the prevalence and molecular epidemiology of S. aureus coloniza-
tion in hospitalized patients from that region, and compared their
features with those of the few S. aureus clinical isolates available
from that setting.
2. Methods
2.1. Study design and population
S. aureus colonization was investigated in eight hospitals in
seven small urban areas of the Bolivian Chaco region (Figure 1 and
Supplementary Material Table S1). All hospitals are small
healthcare units with 20 to 78 beds (Supplementary Material
Table S1), and together are representative of the organization of
the hospital care system in this area. Facilities for microbiological
diagnosis of skin and soft tissue infections (SSTIs) were not
available at these hospitals, with the exception of one of them – the
hospital of Villa Montes. This hospital has performed microbio-
logical analyses since mid-2010, although a very limited number of
samples are processed.
The survey was a point prevalence study performed twice (on
August 2–3, 2012, and on August 12–17, 2013). All individuals
hospitalized during the study periods were considered eligible.
After providing written informed consent (obtained from the
parents or legal guardians in the case of a minor), samples were
obtained from each patient for the detection of S. aureus
colonization (see below). Full ethical clearance was obtained from
the qualiﬁed authorities who revised and approved the study
design (Convenio de Salud, Ministerio de Salud – Vicariato de
Camiri, Camiri, Bolivia).For comparison purposes, all S. aureus clinical isolates collected
in the hospital of Villa Montes since the introduction of the clinical
microbiology laboratory were included in the present study (see
below).
2.2. Screening for carriage of S. aureus
The investigation of S. aureus colonization was performed by
obtaining two samples from each participant: a nasal swab (a
single swab for both nares) and an inguinal swab (a single swab for
both groin sides). The nasal and inguinal swabs obtained from each
individual were preserved at 4 8C in Amies transport medium
(Oxoid, Milan, Italy) and transported to the hospital of Camiri,
where the swabs were processed as follows. Each pair of swabs
(from each subject) was inoculated overnight at 35 8C in an
enrichment medium (2 ml) constituted of tryptic soy broth (TSB)
(Oxoid) supplemented with 6.5% NaCl and 25 mg/ml colistin
(prepared by adding 1 disk of colistin 25 mg per millilitre of broth).
Then, 10 ml of the enriched suspension was plated onto mannitol
salt agar (MSA) (Oxoid); the bacterial growth was collected and
preserved in Amies transport medium for transfer to Italy. Here,
each sample was again plated on MSA, and mannitol-fermenting
colonies were subcultured and identiﬁed by matrix-assisted laser
desorption/ionization time-of-ﬂight mass spectrometry (MALDI-
TOF MS system; bioMe´rieux Inc., Marcy l’Etoile, France). For each
sample, only one S. aureus isolate was selected for further analysis.
2.3. In vitro susceptibility testing
Antimicrobial susceptibility testing was performed by disk
diffusion method in accordance with the Clinical and Laboratory
A. Bartoloni et al. / International Journal of Infectious Diseases 30 (2015) 156–160158Standards Institute (CLSI) guidelines.17,18 Antibiotic disks were
purchased from Oxoid. All isolates were tested for susceptibility to
penicillin G, erythromycin, clindamycin, tetracycline, ciproﬂoxa-
cin, trimethoprim–sulfamethoxazole, gentamicin, chlorampheni-
col, and rifampin. In addition, they were investigated for the
methicillin resistance phenotype by cefoxitin screening disk test,
and for inducible clindamycin resistance by D-zone test.18 S. aureus
ATCC 25923 was used as quality control.
2.4. Molecular characterization of S. aureus isolates
PVL genes and the arcA gene (for ACME) were detected by PCR,
as described previously.10 Genotyping was performed by spa
typing,19 multilocus sequence typing (MLST) (http://www.mlst.
net),20 and pulsed-ﬁeld gel electrophoresis (PFGE) following
the CDC protocol (http://www.cdc.gov/HAI/pdfs/labSettings/
ar_mras_PFGE_s_aureus.pdf) and interpreted according to the
criteria proposed by van Belkum et al.21 SCCmec characterization
was achieved following the PCR-based protocols described
previously by Kondo et al. and Milheiric¸o et al. for typing and
subtyping, respectively.22,23
2.5. Clinical isolates
Clinical isolates were collected in the hospital of Villa Montes,
the only one with facilities for the microbiological diagnosis of
SSTIs. During the period May 2010 to August 2013, only 10 S.
aureus clinical isolates were collected from that hospital. This
limited number is related to the fact that microbiological diagnosis
represents an extra cost for the patient and is rarely requested by
physicians. Of the 10 isolates, only nine were available for
investigation. Identiﬁcation was conﬁrmed by MALDI-TOF MS
(bioMe´rieux) and characterization was carried out as described for
S. aureus isolates from colonization.
2.6. Statistical analysis
Statistical differences were determined by Chi-square test
(with Yates’ correction) and Fisher’s exact test when appropriate.
Conﬁdence intervals (95% CI) were calculated using the binomial
distribution.
3. Results and discussion
3.1. Characteristics of the study population
Among all individuals admitted to hospital during the point
prevalence study periods, 280 (2012, n = 90; 2013, n = 190) agreed
to participate in the survey. In 2013, 80% of inpatients consented to
sampling, while no data were available for the 2012 survey.
The male to female ratio of the study participants was 181:99,
and they ranged in age from 1 day to 89 years (mean age 31 years
and median age 26 years; calculated from all but ﬁve patients, for
whom age was not available). Inpatients were admitted to
maternity (n = 93), general medicine (n = 78), surgery (n = 50),
paediatric (n = 45), tuberculosis isolation (n = 7), ﬁrst aid (n = 4),
and intensive care (n = 3) wards. At the time of sample collection,
63% of patients had been hospitalized within the previous 48 h and
77% of them reported no hospitalization during the preceding year.
3.2. Colonization by S. aureus among inpatients from eight hospitals
in the Bolivian Chaco region
An overall moderate prevalence of S. aureus colonization was
detected among the 280 hospitalized individuals included in the
study (n = 41, 14.6%), with no signiﬁcant differences observedbetween the two study periods (17.8% (95% CI 10–27%) and 13.2%
(95% CI 9–19%) in 2012 and 2013, respectively; p = 0.4). Carriers of
S. aureus were found in all hospitals except in Charagua (where
nine inpatients were enrolled in 2012 and 15 in 2013) (Figure 1 and
Supplementary Material Table S1).
Colonization by MRSA isolates was detected with a rate of 1.1%
(95% CI 0–6%) in 2012 and 2.1% (95% CI 0–5%) in 2013 (p = 1), and
involved ﬁve inpatients from three out of the eight hospitals
(Camiri, n = 1; Caraparı´, n = 1; Villa Montes, n = 3) (Figure 1 and
Supplementary Material Table S1). No relevant correlation
between methicillin-sensitive S. aureus (MSSA)/MRSA carriage
and clinical/demographic data was observed (data not shown). The
observed MRSA colonization rate (1.8% of the total studied
population) was overall consistent with the results of a previous
study conducted in the same geographic region in 2008 and 2009,
which revealed MRSA colonization in three out of 196 (1.5%)
healthy individuals from a rural village.16 A similar MRSA
colonization rate was also reported recently in a population-based
study performed in a small city of Brazil (0.9%) and among medical
students in Colombia (1.6%).24,25 The particular healthcare system
of the Bolivian Chaco, based on very small hospitals, and the fact
that 63% of samples were collected within 48 h of admission, could
explain the similar MRSA colonization rates observed in the
community and hospital settings in this region.
3.3. Characterization of S. aureus isolates from carriers
Susceptibility testing revealed overall low resistance rates in S.
aureus isolates from carriers. Among MSSA isolates (n = 36), most
(83%) were non-susceptible to penicillin G, while only a few were
non-susceptible to tetracycline (14%), gentamicin (8%), chloram-
phenicol (6%), and erythromycin (3%, with inducible clindamycin
resistance), and all isolates were susceptible to trimethoprim–
sulfamethoxazole, ciproﬂoxacin, linezolid, and rifampin. MRSA
isolates (n = 5) were susceptible to all of the above non-beta-
lactam antibiotics tested (except for one isolate that was non-
susceptible to erythromycin and ciproﬂoxacin).
MSSA isolates tested negative for mecA and PVL genes, while all
MRSA isolates were found to carry SCCmec IVc, and one of them
was PLV-positive. spa typing analysis revealed a high heterogene-
ity among MSSA isolates (20 different types, including the new spa-
type t13417), without a predominance of any spa-type (Table 1). In
contrast, the ﬁve MRSA isolates were found to belong to two spa-
types: t701 (one isolate in 2012 and three in 2013) and t008 (one
isolate in 2013) (Table 1).
Interestingly, besides being the dominant spa-type among
MRSA isolates in this survey (Table 1), spa-type t701 was also
found in three MSSA isolates from this survey and all of the MRSA
isolates (n = 3) detected in a previous study on MRSA nasal
carriage in a small rural community in the same geographical
setting (Table 2).16 In order to investigate their clonal relation-
ships, the seven MRSA and three MSSA isolates belonging to t701
were subjected to PFGE analysis, which assigned all isolates to the
same clonal lineage (PFGE type A) with a maximum of ﬁve
different bands (Table 2). These data demonstrate that spa-type
t701 is endemic in this area (being detected over a period of
5 years in the microbiota of both healthy individuals and
inpatients), and suggest the likely local evolution of MRSA from
MSSA (or vice versa), as described in other settings.26 MRSA
and MSSA belonging to spa-type t701 are described all over the
world, from infection and colonization, as also reported in the
Ridom SpaServer (http://www.spaserver.ridom.de/). In addition,
a recent publication reported that t701 (harbouring different
SCCmec types) accounted for 30% of MRSA clinical isolates from
diverse hospitals in the west of Iran,27 suggesting a propensity of
this lineage to epidemic dissemination.
Table 2
Features of Staphylococcus aureus isolates from colonization and infection belonging to spa-types t701 and t008
Source Year Isolate Origin Type (population) MRSA/MSSA spa-type PVL SCCmec PFGEc
Colonization 2012 131a Yacuiba Hospital MSSA t701 Neg NA A3
176a Monteagudo Hospital MSSA t701 Neg NA A3
188a Villa Montes Hospital MSSA t701 Neg NA A2
121a Camiri Hospital MRSA t701 Neg IVc A1
Colonization 2013 272a Villa Montes Hospital MRSA t701 Neg IVc A
280a Villa Montes Hospital MRSA t701 Neg IVc A
281a Villa Montes Hospital MRSA t701 Neg IVc A
284a Caraparı´ Hospital MRSAd t008 Pos IVc B
Infectiona 2010–2013 304 Villa Montes Hospital MRSA t008 Pos IVc B
306 Villa Montes Hospital MRSA t008 Pos IVc B
233 Villa Montes Hospital MRSA t008 Pos IVc B
393 Villa Montes Hospital MRSA t008 Pos IVc B1
401 Villa Montes Hospital MRSA t008 Pos IVc B
Colonizationb 140 Gutierrez Community MRSA t701 Neg IVc A
2009 99 Gutierrez Community MRSA t701 Neg IVc A1
132 Gutierrez Community MRSA t701 Neg IVc A1
MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-sensitive Staphylococcus aureus; PVL, Panton–Valentine leukocidin; SCCmec, staphylococcal cassette
chromosome mec; PFGE, pulsed-ﬁeld gel electrophoresis; NA, not applicable.
a All isolates belonging to spa-type t008 were from inpatients, with the exception of isolate 304, which was from an outpatient.
Isolates 304 and 306 were collected in 2011, isolate 233 in 2012, and isolates 393 and 401 in 2013.
b Previously characterized by Bartoloni et al., 2013.16
c Two different bands (A/A1, A2/A3); three different bands (A/A2); ﬁve different bands (A/A3, A1/A2, A1/A3).
d All MRSA isolates remained susceptible to all non-beta-lactam antibiotics tested, with the exception of isolate 284a, which showed intermediate susceptibility to
erythromycin and ciproﬂoxacin.
Table 1
Population structure of Staphylococcus aureus isolates from colonization and infection in patients from eight hospitals in the Bolivian Chaco
Source Year MSSA/ MRSA Number of
isolates
Spa-type (number of isolates)
Colonization 2012 MSSA 15 t189 (n = 3); t701 (n = 3); t359 (n = 2); t2883 (n = 2); t002 (n = 1); t088 (n = 1);
t645 (n = 1); t1671 (n = 1); t6907 (n = 1)
MRSA 1 t701 (n = 1)
Colonization 2013 MSSA 21 t024 (n = 3); t189 (n = 3); t078 (n = 2); t645 (n = 2); t729 (n = 2); t065 (n = 1); t319 (n = 1);
t1166 (n = 1); t1451 (n = 1); t4710 (n = 1); t5365 (n = 1); t6125 (n = 1); t13417 (n = 2)
MRSA 4 t701 (n = 3); t008 (n = 1)
Infectiona 2010–2013 MSSA 4 t002 (n = 1); t021 (n = 1); t088 (n = 1); t645 (n = 1)
MRSA 5 t008 (n = 5)
MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-sensitive Staphylococcus aureus.
a All clinical isolates except three (t645, t088, and one representative of t008) were from inpatients.
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testing positive for PVL genes and showing non-susceptibility to
erythromycin and ciproﬂoxacin (Table 2). MLST assigned it to ST8
(ST8 clonal complex). As ST8, spa-type t008, SCCmec IVc, and PLV
positivity are among the features of USA300 Latin American
variant (USA300-LV), we also tested this isolate for the presence of
ACME. The absence of ACME conﬁrmed that this isolate was related
to USA300-LV, one of the most widespread MRSA clones and
largely dominant in community and hospital settings in northern
countries of Latin America.4,9–13
3.4. Comparison between S. aureus isolates from colonization and
infection
In order to compare S. aureus isolates from colonization and
infection, nine clinical isolates collected from SSTIs in Villa Montes
were also analyzed. They represented all of the S. aureus isolates
collected in that hospital during the period May 2010 to August
2013, with the exception of one isolate that had not been stored.
Four of them (44.4%) were MSSA, showed a susceptibility
phenotype to non-beta-lactam antibiotics, and were negative for
the presence of PVL genes. The remaining ﬁve isolates (55.6%) were
MRSA and were found to share the same features as the MRSA
isolate from colonization belonging to spa-type t008. Indeed, they
were all assigned to spa-type t008, showed a similar PFGE pattern
(PFGE type B), carried SCCmec IVc and PVL genes, and werenegative for the presence of ACME. However, differently from the
isolate from colonization, they remained susceptible to all non-
beta-lactam antibiotics tested.
The low number of S. aureus clinical isolates available for
investigation and the possibility of obtaining clinical isolates from
only one hospital are limitations of the present work. Nonetheless,
USA300-LV was isolated over a 3-year period (i.e., ﬁrst isolate on
January 2011, last isolate on June 2013) and accounted for all
documented MRSA infections. The identiﬁcation of USA300-LV
clinical isolates in the hospital of Villa Montes over an almost
3-year period, together with the detection of one USA300-LV
carrier in a hospital from another urban area, would suggest the
dissemination of this relevant clone in the Chaco region.
4. Conclusions
MRSA is a global public health threat in both the hospital setting
and in the community.1
In this study, we surveyed colonization by S. aureus in patients
from eight hospitals in the Bolivian Chaco, which is a distinct
setting because of the presence of very small hospitals (represen-
tative of the local healthcare system), the absence of facilities for
microbiological diagnosis, and as a consequence, a lack of
microbiological data.
In this context, not studied before, we found a moderate
(14.6%) S. aureus carriage, comparable to data reported previously
A. Bartoloni et al. / International Journal of Infectious Diseases 30 (2015) 156–160160worldwide,28 and an overall low rate (1.8%) of MRSA carriers.
Isolates belonging to spa-type t701 seemed to be the most
prevalent among MRSA, being disseminated in both the hospital
and community setting, but a USA300-LV isolate was also detected.
Of note, representatives of this clone were the only type of
MRSA detected among clinical isolates of S. aureus available for
investigation from the study area, underscoring the clinical and
epidemiological impact of this clone even in this setting.9
Overall, these ﬁndings underscore the importance of imple-
menting infection control measures in similar settings and may
suggest that alternatives to beta-lactams be considered when
empiric antimicrobial therapy is provided for the treatment of an
infection compatible with S. aureus aetiology. All MRSA isolates
were found to be susceptible to several antimicrobials including
ﬁrst-line, oral, and inexpensive drugs such as trimethoprim–
sulfamethoxazole and tetracycline. As the prevalence of resistance
to non-beta-lactam agents could change over time, susceptibility
patterns of S. aureus should continue to be monitored, and the
information used to guide empiric management decisions.
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